Reducing tau aggregates with anle138b delays disease progression in a mouse 
model of tauopathies.

Wagner, J.; Krauss, S.; Shi, S.; Ryazanov, S.; Steffen, J.; Miklitz, C.; Leonov, A.; Kleinknecht, A.; Göricke, B.; Weishaupt, J. H.; Weckbecker, D.; Reiner, A. M.; Zinth, W.; Levin, J.; Ehninger, D.; Remy, S.; Kretzschmar, H. A.; Griesinger, C.; Giese, A.; Fuhrmann, M.

doi:10.1007/s00401-015-1483-3

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.

MPS-Authors

/persons/resource/persons45923

Ryazanov, S.
Department of NMR-based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons15438

Leonov, A.
Department of NMR Based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons15147

Griesinger, C.
Department of NMR Based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

External Resource

http://link.springer.com/content/pdf/10.1007%2Fs00401-015-1483-3.pdf
(出版社版)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

2227894_Suppl.pdf
(付録資料), 505KB

引用

Wagner, J., Krauss, S., Shi, S., Ryazanov, S., Steffen, J., Miklitz, C., Leonov, A., Kleinknecht, A., Göricke, B., Weishaupt, J. H., Weckbecker, D., Reiner, A. M., Zinth, W., Levin, J., Ehninger, D., Remy, S., Kretzschmar, H. A., Griesinger, C., Giese, A., & Fuhrmann, M. (2015). Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathologica, 130(5), 619-631. doi:10.1007/s00401-015-1483-3.

引用: https://hdl.handle.net/11858/00-001M-0000-0029-06FA-0

要旨

Pathological tau aggregation leads to filamentous tau inclusions and characterizes neurodegenerative tauopathies such as Alzheimer's disease and frontotemporal dementia and parkinsonism linked to chromosome 17. Tau aggregation coincides with clinical symptoms and is thought to mediate neurodegeneration. Transgenic mice overexpressing mutant human P301S tau exhibit many neuropathological features of human tauopathies including behavioral deficits and increased mortality. Here, we show that the di-phenyl-pyrazole anle138b binds to aggregated tau and inhibits tau aggregation in vitro and in vivo. Furthermore, anle138b treatment effectively ameliorates disease symptoms, increases survival time and improves cognition of tau transgenic PS19 mice. In addition, we found decreased synapse and neuron loss accompanied by a decreased gliosis in the hippocampus. Our results suggest that reducing tau aggregates with anle138b may represent an effective and promising approach for the treatment of human tauopathies.